The Global Icosapent Ethyl API Market was valued at USD 215 Million in 2024 and is projected to reach USD 368 Million by 2032, growing at a Compound Annual Growth Rate (CAGR) of 8.1% during the forecast period (2024–2032). This robust growth is primarily driven by the escalating global prevalence of cardiovascular diseases, landmark clinical trial outcomes validating efficacy, and the rising demand for high-purity omega-3 fatty acids in both pharmaceutical and nutraceutical applications.

As the pharmaceutical industry intensifies its focus on preventive cardiology and precision therapeutics, the spotlight is on the key API manufacturers who are driving innovation in purification, scalable production, and sustainable sourcing. In this blog, we profile the Top 10 Companies in the Icosapent Ethyl API Industry—a mix of global chemical giants, specialized pharmaceutical ingredient suppliers, and regional innovators shaping the future of cardiovascular treatment.

---

🔟 10. Nissui Pharmaceutical Co., Ltd.

Headquarters: Tokyo, Japan
Key Offering: High-Purity EPA-Ethyl Ester API

Nissui Pharmaceutical, a subsidiary of the Nippon Suisan Kaisha (Nissui) Group, leverages its parent company’s deep expertise in marine biochemistry. The company specializes in the extraction and purification of omega-3 fatty acids, producing icosapent ethyl (EPA-EE) for the Japanese pharmaceutical and functional food markets. Its vertically integrated operations, from fishery resources to finished API, ensure tight quality control and secure raw material supply.

Strategic Initiatives:

• Focus on the high-growth Japanese nutraceutical (FOSHU-approved) sector.
• Investment in advanced molecular distillation for >96% purity grades.
• Strategic positioning to serve the aging demographic with cardiovascular health products.

Download FREE Sample Report: Icosapent Ethyl API Market – View in Detailed Research Report

---

9️⃣ 9. Finorga SAS (A Part of Groupe Novasep)

Headquarters: Chasse-sur-Rhône, France
Key Offering: cGMP EPA-EE for Pharmaceutical Formulations

Finorga, operating under the Novasep umbrella, is a recognized European contract development and manufacturing organization (CDMO) for complex APIs, including highly purified omega-3 derivatives. The company provides pharmaceutical-grade icosapent ethyl under stringent cGMP standards, supporting clients from clinical trial material supply through to commercial launch. Their expertise lies in complex purification and achieving the exacting specifications required for regulatory filings in the EU and US.

Strategic Initiatives:

• Providing end-to-end CDMO services for lipid-based APIs.
• Focus on serving small to mid-sized biopharma companies developing novel omega-3 drug candidates.
• Leveraging Novasep’s continuous chromatography technology for cost-effective high-purity production.

---

8️⃣ 8. Sichuan Gowell Pharmaceutical Co., Ltd.

Headquarters: Chengdu, Sichuan, China
Key Offering: Cost-Competitive Icosapent Ethyl API

Sichuan Gowell is a prominent Chinese manufacturer of pharmaceutical intermediates and APIs, with a growing portfolio in omega-3 derivatives. The company caters primarily to the domestic nutraceutical and generic drug market, offering a cost-effective source of icosapent ethyl. With China’s healthcare system expanding and cardiovascular awareness rising, Gowell is strategically positioned to capture significant regional growth through scalable production.

Strategic Initiatives:

• Expanding production capacity to meet surging domestic demand for cardiovascular health products.
• Pursuing international quality certifications (e.g., EDQM, FDA DMF filings) to enter global supply chains.
• Investing in purification technology upgrades to move into higher-margin, pharmaceutical-grade segments.

---

7️⃣ 7. Bizen Chemical Co., Ltd.

Headquarters: Okayama, Japan
Key Offering: Specialty EPA-Ethyl Ester for Pharma & Supplements

Bizen Chemical is a leading Japanese fine chemical company with a strong focus on esterification technologies and lipid chemistry. The company produces high-quality icosapent ethyl, serving the exacting standards of Japan’s pharmaceutical industry, known for its rigorous quality requirements. Bizen’s strength lies in its consistent product quality, reliable supply, and strong relationships with formulation partners across Asia.

Strategic Initiatives:

• Capitalizing on Japan’s long-standing clinical evidence and prescription culture for EPA-based drugs.
• Developing stabilized ethyl ester formulations to enhance shelf-life and efficacy in finished products.
• Serving as a critical regional supplier in the Asia-Pacific nutraceutical boom.

---

6️⃣ 6. Huatai Pharma Inc.

Headquarters: Nantong, Jiangsu, China
Key Offering: Pharmaceutical and Nutraceutical Grade EPA-EE

Huatai Pharma is a major Chinese player in the API space, with significant investment in omega-3 manufacturing facilities. The company produces icosapent ethyl for both the booming domestic functional food market and for export as a pharmaceutical intermediate. Huatai’s competitive advantage is its large-scale production capacity and growing commitment to meeting international regulatory standards, making it a key supplier in the global cost-competitive segment.

Strategic Initiatives:

• Large-scale capacity expansion to become a leading global supplier of omega-3 APIs.
• Strategic focus on supplying API for generic versions of blockbuster drugs like Vascepa.
• Engaging in partnerships with multinational corporations seeking a Chinese manufacturing base.

Download FREE Sample Report: Icosapent Ethyl API Market – View in Detailed Research Report

---

5️⃣ 5. Axplora (Formerly known as BASF’s Pharma Ingredients & Services)

Headquarters: Mannheim, Germany
Key Offering: High-Purity Icosapent Ethyl & Custom Lipid Solutions

Axplora, born from BASF’s fine chemicals division, is a focused CDMO with deep expertise in lipid and API manufacturing. The company brings a strong legacy of quality and innovation to the icosapent ethyl market. It offers pharmaceutical customers a reliable, cGMP-compliant source of EPA-EE, supported by extensive regulatory experience and a global supply network, making it a trusted partner for complex drug development programs.

Strategic Initiatives:

• Providing tailored lipid API solutions and formulation support beyond mere supply.
• Focusing on sustainability in production processes and raw material sourcing.
• Leveraging its European base to serve as a key supplier for the EU pharmaceutical market.

---

4️⃣ 4. Chemport Inc.

Headquarters: South Plainfield, New Jersey, USA
Key Offering: Ultra-High Purity Icosapent Ethyl (>98%)

Chemport is a U.S.-based leader in the supply of high-purity pharmaceutical intermediates and APIs, with a specialized focus on complex lipids. The company is recognized for supplying ultra-high purity icosapent ethyl, often exceeding standard pharmacopeial requirements, which is critical for sensitive drug formulations and advanced clinical research. Its strategic location and strong quality systems make it a preferred supplier for North American pharmaceutical companies.

Strategic Initiatives:

• Carving a niche in the high-margin, ultra-high purity segment of the market.
• Providing critical supply chain security and regulatory support for U.S. drug developers.
• Investing in advanced analytical and purification technologies to maintain purity leadership.

---

3️⃣ 3. Novasep Holding SAS

Headquarters: Lyon, France
Key Offering: Sustainable, Chromatography-Purified EPA-EE API

Novasep is a global leader in manufacturing solutions for the life sciences industry, renowned for its proprietary chromatography and purification technologies. The company applies its expertise to produce highly purified and sustainable icosapent ethyl, emphasizing reduced environmental impact through innovative processes. Novasep’s strength lies in its ability to offer scalable, cost-effective purification that meets the most demanding pharmaceutical specifications.

Strategic Initiatives:

• Pioneering sustainable and green chemistry approaches to omega-3 API production.
• Promoting continuous manufacturing processes to improve yield and reduce costs.
• Acting as a technology enabler and CDMO for next-generation omega-3 drug products.

---

2️⃣ 2. KD Pharma Group SA

Headquarters: Bex, Switzerland
Key Offering: Highly Concentrated Omega-3 APIs (incl. EPA-EE)

KD Pharma is a pure-play omega-3 specialist and a formidable competitor in the high-purity API space. The company is known for its patented concentration and purification technologies, which allow it to produce icosapent ethyl with exceptional purity profiles (>96% EPA). KD Pharma supplies leading pharmaceutical companies worldwide and has a strong focus on clinical evidence, often partnering in research to expand the therapeutic applications of its ingredients.

Strategic Initiatives:

• Driving innovation in concentration technology to achieve industry-leading purity levels.
• Strategic focus on pharmaceutical partnerships for prescription drug development.
• Exploring alternative sustainable sources, such as algae, for future raw material supply.

---

1️⃣ 1. DSM Nutritional Products Ltd (Now part of Firmenich)

Headquarters: Kaiseraugst, Switzerland
Key Offering: Qualia®-Pure Icosapent Ethyl & Full Omega-3 Portfolio

DSM-Firmenich stands as the undisputed global leader in nutritional and pharmaceutical ingredients, including omega-3s. Through its Qualia®-Pure range, the company supplies premium-grade, fully traceable, and sustainably sourced icosapent ethyl API to the world’s largest pharmaceutical manufacturers. Its unmatched scale, vertically integrated supply chain (including algal omega-3 capabilities), and deep regulatory expertise make it the partner of choice for blockbuster drugs like Vascepa, securing its top position.

Strategic Initiatives:

• Leading the industry transition towards sustainable, algae-based omega-3 production.
• Massive investment in R&D for new health benefits and patent-protected formulations.
• Providing comprehensive support from API supply to finished dosage form development for global clients.

Get Full Report Here: Icosapent Ethyl API Market – View in Detailed Research Report

---

🌍 Outlook: The Future of Icosapent Ethyl API is Sustainable and Precision-Driven

The Icosapent Ethyl API market is undergoing a significant evolution. While demand from established cardiovascular drugs continues to be strong, the industry is investing heavily in sustainable sourcing, advanced purification, and expanded therapeutic applications.

📈 Key Trends Shaping the Market:

• Accelerated shift from marine to algal-derived EPA for supply chain security and sustainability.
• Increasing regulatory scrutiny and demand for ultra-high purity (>96%) for new drug applications.
• Growth of the Asian nutraceutical market creating a dual-demand channel for API.
• Strategic CDMO partnerships becoming critical for pharmaceutical companies to manage complex manufacturing.

Get Full Report Here: Icosapent Ethyl API Market – View in Detailed Research Report

The companies listed above are not only supplying a critical pharmaceutical ingredient—they are enabling the next wave of preventive cardiology and metabolic health solutions worldwide.